3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
18
Nivolumab
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
aldesleukin
4
Paclitaxel
4
Irinotecan
4
Gemcitabine
4
Docetaxel
4
Cisplatin
4
sargramostim
3
atezolizumab
3
Topotecan
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
temsirolimus
2
talazoparib
2
carfilzomib
2
cabozantinib
2
budigalimab
2
Trastuzumab
2
Therapeutics
2
Taxes
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Injections
2
Gene Expression Profiling
2
Fulvestrant
2
Fluorodeoxyglucose F18
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
tinostamustine
×
Gynecologic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts